Vor to present new data on its cell and genome engineering platform at sitc annual meeting

Cambridge, mass., nov. 09, 2021 (globe newswire) -- vor biopharma (nasdaq: vor), a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel cell therapy platform at the society for immunotherapy of cancer (sitc) 36th annual meeting, taking place in washington d.c., from november 10-14, 2021.
VOR Ratings Summary
VOR Quant Ranking